Skip to main content

Perceptive Advisors — Portfolio, Page 4

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

224
Companies
$26.6B
Total invested
$135.1M
Avg. check
24
Industries
Health Care 17Biotechnology 16Medical 13Therapeutics 6Biopharma 5Genetics 4+18 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 7396 of 224
GenSight Biologics
March 2026

GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases.

Biotechnology · Paris$2.0M Post-IPO Equity
Juno Diagnostics
March 2023

Juno Diagnostics is a healthcare technology company developing the next generation cell-free DNA-based noninvasive prenatal test solutions.

Biotechnology · San Diego$200K Undisclosed
Applied Therapeutics
February 2024

Applied Therapeutics uses drug-development approach to target molecules and pathways that has roles in fatal or debilitating diseases.

Biotechnology · New York$100.0M Post-IPO Equity
COMPASS Pathways
February 2026

Compass Pathways is a mental health care company that focuses on developing therapies for treatment-resistant depression.

Biotechnology · Altrincham$200.0M Post-IPO Equity
Beam Therapeutics
February 2026

Beam Therapeutics is a biotechnology company developing precision genetic medicines through the use of base editing technology.

Biotechnology · Cambridge$100.0M Post-IPO Debt
VitalConnect
February 2025

VitalConnect offers wearable biosensor technology for wireless patient monitoring in both hospital and remote patient populations.

Biotechnology · San Jose$100.0M Venture - Series Unknown
Fusion Pharmaceuticals
February 2023

Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing radiopharmaceuticals.

Biopharma · Hamilton$60.0M Post-IPO Equity
Xilio Therapeutics
February 2026

Xilio Therapeutics is a biotechnology company that develops tumor-activated immuno-oncology therapies.

Biopharma · Waltham$40.0M Post-IPO Equity
Kardigan
October 2025

Kardigan develops personalized medicines using AI and data to target and treat the root causes of cardiovascular diseases.

Biopharma · South San Francisco$254.0M Series B
Twin Health
August 2025

Twin Health is a metabolic health platform that offers sensors, AI to reverse, prevent and improve chronic metabolic diseases.

Artificial Intelligence (AI) · Mountain View$53.0M Series E
Avalyn Pharma
July 2025

Avalyn Pharma is a biopharma company developing therapies for the treatment of idiopathic pulmonary fibrosis and other respiratory diseases.

Biopharma · Seattle$100.0M Series D
Zucara Therapeutics
May 2025

Zucara Therapeutics is developing the first once-daily therapeutic to prevent hypoglycemia (low blood sugar) in patients with diabetes.

Biotechnology · Vancouver$5.0M Series B
Orpyx Medical Technologies
September 2024

Orpyx Medical Technologies develops sensor-based technologies and self-monitoring devices in medical and athletic spaces.

Diabetes · Calgary$20.0M Venture - Series Unknown
Genome Medical
September 2024

Genome Medical is a telegenomics technology and services company allowing access to genomic-based medicine.

Genetics · South San Francisco$75.3M Venture - Series Unknown
Bridge to Life Ltd.
August 2024

Bridge to Life is a supplier of preservation solutions globally with a focus on innovation in organ preservation and machine perfusion.

Biotechnology · Northbrook$1.0M Venture - Series Unknown
Pheon Therapeutics
May 2024

Pheon Therapeutics is an Antibody-Drug Conjugate (ADC) specialist that creates ADCs for a variety of difficult-to-treat cancers.

Biotechnology · London$120.0M Series B
Adaptilens
April 2024

Adaptilens is a developer of an accommodating intraocular lens.

Health Care · Boston$17.5M Series A
Neurosterix
April 2024

Neurosterix is a biopharmaceutical firm dedicated to creating allosteric modulators for the treatment of neurological illnesses.

Biopharma · Geneva$63.0M Series A
AsclepiX Therapeutics
July 2023

AsclepiX Therapeutics is a biotech company that develops novel therapeutics to revolutionize the treatment of retinal diseases and cancer.

Biotechnology · Baltimore$10.0M Series A
VivoSense
January 2023

VivoSense is an advancing clinical research with wearable sensor solutions.

Biotechnology · Newport CoastGrant
Cue
January 2022

Cue is a healthcare technology company that enables people to manage their health through actionable and connected health data.

Health Care · San DiegoGrant
AvengeBio
January 2022

AvengeBio is focusing on Cell-Generated Immunotherapies to eradicate solid tumors.

Biotechnology · Cambridge$45.0M Series A
GeneDx
January 2023

GeneDx uses artificial intelligence and machine learning to analyze patient data to provide insights to transform the practice of medicine.

Analytics · Stamford$150.0M Post-IPO Equity
Pear Therapeutics
December 2021

Pear Therapeutics is a software-based digital therapeutics platform designed to treat disease and enhance the efficacy of pharmaceuticals.

Biotechnology · Boston$125.0M Post-IPO Equity

Where Perceptive Advisors invests

Health Care17
Biotechnology16
Medical13
Therapeutics6
Biopharma5
Genetics4

About Perceptive Advisors's portfolio

How many companies has Perceptive Advisors invested in?

Perceptive Advisors has invested in 224 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Perceptive Advisors invest in?

Perceptive Advisors's top investment sectors include Health Care, Biotechnology, Medical, Therapeutics, Biopharma. The firm invests across 24 different industry categories.

What is Perceptive Advisors's largest investment?

Among tracked funding rounds, Kardigan received $254.0M in a Series B round. Perceptive Advisors's total known invested capital is $26.6B.

What is the average investment size for Perceptive Advisors?

Perceptive Advisors's average investment size is $135.1M across its portfolio of 224 companies.

What are Perceptive Advisors's most recent investments?

Recent Perceptive Advisors portfolio additions include GenSight Biologics, Juno Diagnostics, Applied Therapeutics, COMPASS Pathways, Beam Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 224 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →